A Randomized, Double-Blind, Placebo Controlled Study to Evaluate

Recruiting

1 years - 100 years

All

Phase 3

1 Location

Brief description of study

The research study is being conducted to see how well the investigational drug, Nefecon, works for the treatment of your kidney disease and more specific for patients with "primary immunoglobulin A nephropathy," called IgAN.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: IgAN,primary immunoglobulin A nephropathy
Age: 1 years - 100 years
Gender: All

Updated on 04 Aug 2024. Study ID: 833614

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)

Brief description of study

Eligibility of study

Find a site

Interested in the study